Q-omics provides the consensus-scored NDRG3 profile across patient tissues and cancer cell-line models. NDRG3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDRG3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NDRG3 protein abundance shows 30,569 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where NDRG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDRG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDRG3 survival associations across molecular data types. NDRG3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDRG3 RNA expression–survival associations across cancer types. High NDRG3 expression shows unfavorable associations in UVM, LIHC, KICH and OV, but favorable associations in READ and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDRG3 RNA expression.
This table summarizes NDRG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDRG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDRG3 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, STAD, BRCA and CHOL. The HNSC box plot shows higher NDRG3 RNA expression in tumor versus normal tissue (log2 FC = +0.731, t-test p < 0.001).
This table shows molecular features associated with NDRG3 in patient tissues and cancer cell lines. In patient samples, NDRG3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDRG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and PANCREAS.
